Loading...
•
Mar 31, 2021
Vanda Q1 2021 Earnings Report
Reported strong revenue growth across commercial portfolio with the launch of HETLIOZ® in the new indication of nighttime sleep disturbances in patients with Smith-Magenis Syndrome and made significant progress in clinical programs.
Key Takeaways
Vanda Pharmaceuticals reported a total revenue of $62.7 million for Q1 2021, an 8% increase compared to Q1 2020. The company also reported a net income of $8.7 million, compared to $0.5 million in the first quarter of 2020.
Total revenues were $62.7 million, an 8% increase compared to Q1 2020.
HETLIOZ® net product sales were $39.3 million, an 11% increase compared to Q1 2020.
Fanapt® net product sales were $23.3 million, a 3% increase compared to Q1 2020.
Income before taxes was $10.4 million compared to $1.2 million in Q1 2020.
Forward Guidance
Vanda expects to achieve total revenues between $270 to $300 million, HETLIOZ® net product sales between $180 to $200 million, Fanapt® net product sales between $90 to $100 million and year-end cash greater than $400 million in 2021.
Positive Outlook
- Total revenues between $270 to $300 million
- HETLIOZ® net product sales between $180 to $200 million
- Fanapt® net product sales between $90 to $100 million
- Year-end cash greater than $400 million
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...